Search Results for: "grants/list-of-grants-by-id"

Learn about some of these groundbreaking research projects and how they are advancing earlier detection, risk reduction, treatments, and, ultimately, a cure for glaucoma.

Dr. Diane Bovenkamp highlights several of this year’s groundbreaking projects and explain how they’re driving progress in early detection, risk reduction, new treatments—and ultimately, a cure.

This brochure covers what clinical trials are, what volunteering for a trial means to you, what you should consider before participating, and how you are helping researchers impact the lives of millions of people.

The featured speaker was Goldis Malek, PhD, of Duke University. Dr. Malek's lab is focused on investigating the mechanisms underlying age-related macular degeneration, and to hopefully identify therapeutic targets for this debilitating degenerative eye disease.

Join us as lead scientist Dr. Miia Kivipelto discusses the science behind lifestyle interventions for reducing Alzheimer’s risk.

Cognito Therapeutics CEO Brent Vaughan spoke about the pivotal HOPE Study, which uses an investigational medical device consisting of headphones and eyewear to deliver sensory stimulation treatment in the comfort of people’s homes.

Learn about practical tips for maintaining quality of life with low vision.

Explore groundbreaking macular degeneration research. Learn about research aimed at earlier detection, prevention, and ultimately a cure.

Can light and sound help slow Alzheimer’s? Join Christian Howell, CEO of Cognito Therapeutics, as he shares the latest on the HOPE Study. Discover how non-invasive 40 Hz light and sound stimulation may protect memory, thinking, and daily function—and what’s next for this promising technology.

The telephone discussion features Dr. Gayatri S. Reilly of The Retina Group of Washington, who has excelled in research, patient care, and educating other eye care professionals about treating diseases such as age-related macular degeneration (AMD).

Learn about new therapies for diseases of abnormal blood vessel growth such as age-related macular degeneration.

Priyatham S. Mettu, MD, is a Duke University retina specialist who is testing new treatments and new imaging technologies for age-related macular degeneration.

Join Dr. Ali R. Rezai, a leader in neuroscience and neuromodulation, for a live conversation on how focused ultrasound is opening new possibilities in Alzheimer’s research and care.

Learn about the benefits and risks of online tests for dementia, and why it is crucial to involve your healthcare provider.

There is no wonder drug or miracle cure for Alzheimer’s and related dementias, but research studies show that lifestyle choices can cut down your risk.

Learn how to adapt to life with macular degeneration. Discover practical support techniques to manage vision loss effectively.

Join Dr. Beau Ances of Washington University in St. Louis to learn about the emerging science linking gut health and brain health.

The telephone discussion features Deirdre Johnston, MD, a geriatric psychiatrist at Johns Hopkins University.

This Mental Health Awareness Month, join psychologist Ed McDaniel for an honest conversation about the emotional impact of vision loss from age-related macular degeneration (AMD) and geographic atrophy.

Learn about the role that genes play in the risk of developing the early- and late-onset forms of Alzheimer’s disease.

Although there is no cure for Alzheimer’s disease, certain treatments can help control or delay its symptoms, particularly in the early stages of the disease. Learn about the various types of treatment options available.

Dr. Randall J. Bateman took a deep dive into the latest and greatest methods that can lead to earlier detection of dementias.

Learn about emotional coping strategies and understanding the range of feelings that come with an age-related macular degeneration diagnosis.

Rob Howden and Diane Marshall share their journey with Geographic Atrophy, an advanced form of dry macular degeneration.

Hear about the latest advancements in macular degeneration treatments, the role of inflammation, drug development, and therapeutic approaches.

Can everyday lifestyle choices really protect your memory? Dr. Laura Baker, professor at Wake Forest University School of Medicine, will share results from the groundbreaking U.S. POINTER trial—the largest study of its kind to test how lifestyle changes impact brain health.

Join us for a fascinating conversation with Dr. Lucy Q. Shen as we explore cutting-edge research into restoring vision loss from glaucoma.

Macular degeneration expert Dr. Benjamin Kim discussed ongoing clinical trials for the treatment of geographic atrophy.

Guest speakers Sara Brown and Dan Roberts from Prevent Blindness discuss eye health advocacy.

Get the answers to frequently asked questions about Alzheimer's disease.

Join us for an in-depth discussion on the latest developments in wet age-related macular degeneration treatment.

This resource discusses warning signs and ways to reduce the stress associated with caregiving for a person with Alzheimer's.

With over two-thirds (67%) of new grants awarded to women, BrightFocus Foundation is a preeminent funder of female scientists across eye and brain research.

Private research nonprofit BrightFocus Foundation today announced nearly $13 million in grants to support early investigative research into Alzheimer’s disease, macular degeneration, and glaucoma.

BrightFocus Foundation’s Alzheimer’s Fast Track workshop was held Nov. 8-10 in Washington, D.C. and convened 80 talented Alzheimer’s researchers from 19 U.S. states and six countries, including Japan, Spain, and Sweden.

BrightFocus Foundation has announced the awarding of research grants to three scientists at Johns Hopkins University: Resham Chhabra, PhD, Fengquan Zhou, PhD, and Michael Paulaitis, PhD.

The U.S. Food and Drug Administration grants full approval for Leqembi, the first drug in the class of amyloid immunotherapies shown to slow cognitive decline and receive full FDA approval.

More than 75 graduate students, postdoctoral fellows, and other early-career scientists from around the world participated in this year’s BrightFocus Alzheimer’s Fast Track, Nov. 9-11, 2022, in San Diego.

BrightFocus Foundation today announced a request for proposals for projects supported through its Macular Degeneration Research program. The deadline for Letters of Intent is July 29, 2021 for projects beginning in 2022.

Interview with husband and wife co-investigators on past BrightFocus grants, Sarah Doyle, PhD, and Matthew Campbell, PhD, who have made ground-breaking discoveries into the biology of neurodegeneration.

BrightFocus Foundation received a $3.2 million grant from an anonymous foundation to support 12 new Alzheimer’s Disease Research grants.

The annual BrightFocus Vision Research Awards honor outstanding scientists who are advancing macular degeneration and glaucoma research.

Through its National Eye Institute, NIH awarded one of its “Audacious Goals” grants to a team comprised entirely of current and former NGR grantees.

Global nonprofit BrightFocus Foundation announced it has awarded 65 new biomedical research grants to prevent, treat, and cure Alzheimer’s disease, macular degeneration, and glaucoma.

BrightFocus Foundation today announced 93 new research grants, a $17.8 million commitment toward ending these age-related neurodegenerative diseases.

With funding from Macular Degeneration Research, Dr. Daisy Shu is exploring advanced drug delivery systems that release medicine slowly over time. This innovative approach could reduce the number of injections needed for macular degeneration while maintaining vision-saving results.

Students and senior Alzheimer’s researchers gathered in Chicago for an immersive workshop hosted by BrightFocus Foundation.

BrightFocus proudly supports over 200 cutting-edge research grants, fueling the global fight against Alzheimer’s disease, macular degeneration, and glaucoma.

BrightFocus Foundation’s newly released research portfolios highlight the more than 250 active grants across our Alzheimer’s Disease Research, National Glaucoma Research, and Macular Degeneration Research programs in pursuit of discovering cures.

University of Pennsylvania Professor Virginia M.Y. Lee, PhD, who helped develop and guide BrightFocus Foundation’s Alzheimer’s Disease Research program, has won a 2020 Breakthrough Prize in Life Sciences.

BrightFocus Foundation today announced $16.2 million for 76 new research grants, a record high for the organization.

Individuals experiencing symptoms of dementia can now be evaluated using a blood sample drawn at a physician’s office, without the need for expensive and invasive diagnostic testing.

BrightFocus Foundation presented its inaugural Alzheimer’s Disease Research Distinguished Investigator awards to two leading researchers.

BrightFocus Foundation was honored on April 22 by the Association for Research in Vision and Ophthalmology (ARVO) in New Orleans.

BrightFocus Foundation announces $23.8 million in new 2022 grants, a five-fold increase in funding from a decade ago.

In this Q&A, BrightFocus VP of Scientific Affairs Diane Bovenkamp, PhD, explains what geroscience is and how the field may be a huge ally in the search for treatments and cures for Alzheimer’s, macular degeneration, and glaucoma.

Joel Schuman, MD is interviewed by MSNBC’s Richard Lui following the BrightFocus Scientific Impact Award presentation.

BrightFocus Foundation today announced $13.5 million in new scientific research grants seeking cures for Alzheimer’s disease, macular degeneration, and glaucoma.

A team of BrightFocus Alzheimer’s Disease Research-funded scientists is exploring how home-based brain stimulation could improve memory, mood, and daily life for people living with Alzheimer’s disease.

A BrightFocus Foundation Macular Degeneration Research grant recipient aims to bridge the gap in available testing for AMD and detect the condition as early as possible.

Husband and wife research team Bruce Ksander and Meredith Gregory-Ksander express gratitude for the critical early support from BrightFocus grants that set them on their current path.

BrightFocus is once again in the middle of leading Alzheimer’s Fast Track, a several day incubator for some of the world’s most promising early career researchers.

BrightFocus Foundation today recognized six scientists studying macular degeneration and glaucoma, awarding research grants named in honor of leaders in vision science.

BrightFocus Foundation today announced a record $13.3 million in new grants for promising science toward finding cures for Alzheimer’s disease, macular degeneration, and glaucoma.

A BrightFocus Alzheimer’s Disease Research-funded scientist is investigating how “jumping genes” may fuel brain inflammation in Alzheimer’s—and whether blocking them could prevent or slow dementia.

BrightFocus Foundation's new national public service announcements raise awareness of macular degeneration and glaucoma, leading causes of irreversible blindness among people age 50 and older in the U.S.

A National Glaucoma Research-funded scientist is pioneering the use of artificial intelligence and telemedicine to detect glaucoma earlier, improve access to care, and prevent irreversible blindness.

The proposed 2026 federal budget released by the Trump administration would deliver crippling cuts to the National Institutes of Health (NIH). These cuts would threaten essential progress in the fight against Alzheimer’s disease, macular degeneration, and glaucoma—diseases of mind and sight impacting 1 in 7 Americans over age 40.

The annual BrightFocus Vision Research Awards honor outstanding scientists pursuing groundbreaking macular degeneration and glaucoma research.